Friday 6 November 2026 Export INSM’s income statement to Excel — free account

Insmed, Inc.

INSM Healthcare Biotechnology

Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.

Revenue: +268.4%
EPS: +73.8%
Free cash flow: +81.1%
Total debt: +0.27%

Quarter to September 2026, against a year earlier

Revenue growth 5 yrs

111.86 3.10 +2.85%

Follow INSM

Alert me

Market cap: $23.9B
P/E: 0.0×
Fwd P/E: −64.6×
Dividend yield: —
F-score: 4/9
Altman Z: 9.29
Beneish M: −1.90
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Insmed, Inc. (INSM) revenue by segment, product and region

Revenue by product or service $m

Line	FY2025	FY2024	FY2023
ARIKAYCE external R&D expenses	434 71.53%	364 100.00%	305 100.00%
BRINSUPRI	173 28.47%	0 0.00%	0 0.00%
Revenue	606	364	305

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022
Reportable Segment	606 100.00%	364 100.00%	305 100.00%	245 100.00%
Revenue	606	364	305	245

Gross profit by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022
Reportable Segment	‡	‡	‡	‡
Gross profit	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
US	453 74.69%	255 70.06%	224 73.46%	186 75.81%	160 84.64%	158 95.81%
International	153 25.31%	109 29.94%	81 26.54%	—	—	—
Japan	—	—	—	57 23.03%	16 8.49%	0 0.00%
Europe and rest of world	—	—	—	3 1.16%	13 6.87%	7 4.19%
Revenue	606	364	305	245	188	164

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.